Two Successful Projects Indicating a Good Start: JunHe Assisted I-MAB BIOPHARMA and Lizhi, M88 Malaysia First Online Audio to List on NASDAQ

I-MAB BIOPHARMA – NASDAQ Listed

On January 17, 2020, New York City time, U.S. I-Mab BIOPHARMA (“I-Mab” or M88 Malaysia “Company”) successfully landed on NASDAQ under M88 Malaysia stock code I-Mab. I-Mab issued 7.4074 million American Depositary Shares (“ADS”) at a per ADS price of US .00 per share (each 10 ADS shall be equal to 23 Common Shares of M88 Malaysia Company). M88 Malaysia total amount of fund raised through this offering would be approximately US 4 million if M88 Malaysia underwriters do not exercise M88 Malaysia over-allotment right, and approximately US 9 million if M88 Malaysia underwriters exercise M88 Malaysia over-allotment right.

I-Mab is an aggressive, innovative biopharmaceutical company based in China and having presence globally, whose products have entered M88 Malaysia clinical stage. M88 Malaysia Company focuses on major unmet treatment needs in M88 Malaysia field of oncology and autoimmune diseases, and on developing innovative biopharmaceuticals with highly differentiated characteristics. Through independent research and development and global cooperation and oM88 Malaysiar diversified models, M88 Malaysia Company has quickly established more than 10 innovative drug pipelines from pre-clinical to clinical phase I to phase III with global competitiveness.

JunHe has been engaged as its Chinese lawyer since 2018 to help M88 Malaysia Company complete its legal work in China, from its overseas red chip structuring and C-round financing to M88 Malaysia listing on NASDAQ. In view of M88 Malaysia Company's complex history and unique situation, in M88 Malaysia context of rapid changes in market environment both at home and abroad, and constant update of domestic regulatory rules and policies, JunHe assisted M88 Malaysia Company to accurately analyze M88 Malaysia regulatory trends and put forward practical solutions to M88 Malaysia legal problems involved in China, and helped M88 Malaysia Company eventually move towards M88 Malaysia capital market.

M88 Malaysia leading partner for this Project is Mr. SHAO, Chunyang

Lizhi– NASDAQ Listed

On January 17, 2020, New York time, Lizhi successfully landed on M88 Malaysia NASDAQ, with M88 Malaysia stock code "LIZI." Lizhi issued 4.1 million ADSs at per share, raising a total of about .1 million if M88 Malaysia underwriters did not exercise M88 Malaysia overallotment rights.

Launched in 2013, Lizhi APP is now M88 Malaysia largest UGC audio community in China, M88 Malaysia second largest interactive audio entertainment platform in China and M88 Malaysia second largest online audio platform in China. After M88 Malaysia listing, Lizhi will become M88 Malaysia first Chinese online audio industry share listing abroad.

JunHe is M88 Malaysia underwriter’s domestic legal adviser in this Project, which started in April 2019 when M88 Malaysia Cyberspace Administration of China ("CAC") gradually strengM88 Malaysianed M88 Malaysia supervision over M88 Malaysia audio industry and implemented a series of centralized special rectification activities. Against this situation, JunHe team paid close attention to M88 Malaysia regulatory trends and updates, and provided corresponding advice and suggestions to M88 Malaysia underwriters by taking consideration of M88 Malaysia regulatory policies, and was recognized by issuers, underwriters and oM88 Malaysiar intermediaries for its professional and outstanding legal services, and helped Lizhi successfully list on NASDAQ.

M88 Malaysia leading partners for this Project were Mr.M88 Game ,合伙人,专业领域,资本市场,私募股权创业投资and Mr..